Zhaoke Ophthalmology's IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE
* Targets broadest patient group – three to 17 years old * Two concurrent clinical trials, one leveraging global study to accelerate time to market * Phase III clinical trials testing two different doses to tailor for individual patients HONG KONG, Sept. 29, 2021 /PRNewswire/ -- Zhaoke Opht...
Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint
Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in China Zhaoke Ophthalmology's in-house developed innovative drug candidate Targeting NDA Filing by the End of 2021 Dry Eye Disease Affects Over 200 Million People in China Potential to become new standard of care for moderate-to-s...
Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdong Medical Products Administration
HONG KONG, May 24, 2021 /PRNewswire/ -- Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announc...
